Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study

BACKGROUND: Interleukin-13 receptor α 2 (IL13Rα2) is a promising tumor-directed antigen of malignant glioma (MG). Here, we examine the efficacy and safety of T cells containing a YYB-103 chimeric antigen receptor (CAR) that can preferentially bind to IL13Rα2 on MG cells. METHODS: IL13 was modified o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kiwan, Gwak, Ho-Shin, Han, Nayoung, Hong, Eun Kyung, Choi, Beom K., Lee, Sangeun, Choi, Soyoung, Park, Ju-Hwang, Seok, Ji-Hye, Jeon, Yeongha, Cho, Hyuntae, Lee, Song-Jae, Lee, Yura, Nam, Ki Taek, Song, Seong-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606595/
https://www.ncbi.nlm.nih.gov/pubmed/34819930
http://dx.doi.org/10.3389/fimmu.2021.715000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606595/
https://www.ncbi.nlm.nih.gov/pubmed/34819930
http://dx.doi.org/10.3389/fimmu.2021.715000

Ejemplares similares